日本語フィールド
著者：Masahiro Natsuaki, Shinjo Sonoda, Goro Yoshioka, Hiroshi Hongo, Tetsuya Kaneko, Kuninobu Kashiyama, Kensuke Yokoi, Yutaka Hikichi, Koichi Node題名：Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives 発表情報：Cardiovasc Interv Ther 巻: 37 号: 2 ページ: 255-263キーワード：Antiplatelet therapy; Antithrombotic therapy; Percutaneous coronary intervention概要：Antiplatelet therapy after percutaneous coronary intervention (PCI) has been changing in parallel with the development of drug-eluting stents (DES) and antiplatelet agents. The recommendation of dual antiplatelet therapy duration is getting shorter due to the decreased risk of stent thrombosis in new-generation DES, the use of a P2Y12 inhibitor as a monotherapy, and the increasing prevalence of high bleeding risk patients. Antithrombotic therapy after PCI has also changed due to the introduction of direct oral anticoagulants. Aspirin-free P2Y12 inhibitor monotherapy is now being evaluated in several prospective studies as a novel strategy of antiplatelet therapy after PCI. This review shows a current status and provides future perspectives for the antiplatelet therapy after PCI. 抄録：英語フィールド
Author：Masahiro Natsuaki, Shinjo Sonoda, Goro Yoshioka, Hiroshi Hongo, Tetsuya Kaneko, Kuninobu Kashiyama, Kensuke Yokoi, Yutaka Hikichi, Koichi NodeTitle：Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives Announcement information:Cardiovasc Interv Ther Vol: 37 Issue: 2 Page: 255-263Keyword：Antiplatelet therapy; Antithrombotic therapy; Percutaneous coronary interventionAn abstract：Antiplatelet therapy after percutaneous coronary intervention (PCI) has been changing in parallel with the development of drug-eluting stents (DES) and antiplatelet agents. The recommendation of dual antiplatelet therapy duration is getting shorter due to the decreased risk of stent thrombosis in new-generation DES, the use of a P2Y12 inhibitor as a monotherapy, and the increasing prevalence of high bleeding risk patients. Antithrombotic therapy after PCI has also changed due to the introduction of direct oral anticoagulants. Aspirin-free P2Y12 inhibitor monotherapy is now being evaluated in several prospective studies as a novel strategy of antiplatelet therapy after PCI. This review shows a current status and provides future perspectives for the antiplatelet therapy after PCI. 